| Dry eye symptoms | Pooling studies found that dry eye symptoms decreased on average with the products studied; study results varied greatly.Standardised mean difference −1.02, 95% CI −1.51 to −0.53; I² 97% | 1/4 Very lowStudies were small or had methodological shortcomings; missing data and selective reporting are possible. Results varied greatly or were heterogeneous. Different products, administration methods, participant groups or indirect measures were used. A confidence interval is provided, but the precision of the pooled estimate remains uncertain. The influence of publication bias could not be assessed. | 11 systematic review; 16 trials for this outcomeThe effects of different forms of omega-3 polyunsaturated fatty acids on dry eye disease resulting from various etiologies: a meta-analysis and systematic review. ↗ | Adults with dry eyes of various causes, including meibomian gland dysfunction, contact lens use, after surgery, rosacea or Sjögren's syndrome. | - The effects of different forms of omega-3 polyunsaturated fatty acids on dry eye disease resulting from various etiologies: a meta-analysis and systematic review. ↗
|
|---|
| Overall thinking test score | No convincing average improvement in the overall thinking test score was found.Standardised mean difference 0.041, 95% CI −0.108 to 0.190 | 2/4 LowSome studies were small, with a risk of bias and incomplete reporting. Interventions and outcomes varied; study results could conflict. The assessment is limited to the stated group and measured outcome. The pooled result and confidence interval are provided. Publication bias cannot be ruled out. | 11 systematic review; 24 trials in the whole reviewThe influence of n-3 polyunsaturated fatty acids on cognitive function in individuals without dementia: a systematic review and dose-response meta-analysis. ↗ | Adults aged 40 and over without dementia, including people with mild cognitive impairment. | - The influence of n-3 polyunsaturated fatty acids on cognitive function in individuals without dementia: a systematic review and dose-response meta-analysis. ↗
|
|---|
| Muscle strength | No convincing average increase in muscle strength was found.Standardised mean difference −0.02, 95% CI −0.38 to 0.34; very low certainty | 1/4 Very lowStudies were small or had methodological shortcomings; missing data and selective reporting are possible. Results varied greatly or were heterogeneous. Different products, administration methods, participant groups or indirect measures were used. A confidence interval is provided, but the precision of the pooled estimate remains uncertain. The influence of publication bias could not be assessed. | 11 systematic review; 8 trials for this outcomeOmega-3 supplementation shows no clear benefit for fat-free mass or muscle strength in healthy adults: a systematic review and meta-analysis of randomized controlled trials. ↗ | Healthy adults without obesity; eight studies and 22 interrelated strength measures. | - Omega-3 supplementation shows no clear benefit for fat-free mass or muscle strength in healthy adults: a systematic review and meta-analysis of randomized controlled trials. ↗
|
|---|
| Muscle soreness after exercise | The EPA and DHA products studied reduced peak muscle soreness after unfamiliar exercise that lengthens the working muscle.Hedges g −0.75, 95% CI −1.14 to −0.36; I² 45.1% | 2/4 LowSome studies were small, with a risk of bias and incomplete reporting. Interventions and outcomes varied; study results could conflict. The assessment is limited to the stated group and measured outcome. The pooled result and confidence interval are provided. Publication bias cannot be ruled out. | 11 systematic review; 9 trials for this outcomeEffects of LC n-3 PUFA Supplementation on Muscle Pain, Function, and Damage Markers in Healthy Young to Middle-Aged Adults Following Acute or Chronic Exercise: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ↗ | Participants in nine placebo-controlled studies of exercise that lengthens the working muscle. | - Effects of LC n-3 PUFA Supplementation on Muscle Pain, Function, and Damage Markers in Healthy Young to Middle-Aged Adults Following Acute or Chronic Exercise: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ↗
|
|---|
| Pain in rheumatoid arthritis | No convincing average reduction in pain was found.Standardised mean difference −0.16, 95% CI −0.40 to +0.09 | 1/4 Very lowStudies were small or had methodological shortcomings; missing data and selective reporting are possible. Results varied greatly or were heterogeneous. Different products, administration methods, participant groups or indirect measures were used. A confidence interval is provided, but the precision of the pooled estimate remains uncertain. The influence of publication bias could not be assessed. | 11 systematic review; 23 trials in the whole reviewEfficacy of n-3 fatty acid supplementation on rheumatoid arthritis' disease activity indicators: a systematic review and meta-analysis of randomized placebo-controlled trials. ↗ | Adults with rheumatoid arthritis; the review included 23 placebo-controlled studies. | - Efficacy of n-3 fatty acid supplementation on rheumatoid arthritis' disease activity indicators: a systematic review and meta-analysis of randomized placebo-controlled trials. ↗
|
|---|
| Water loss through the skin | In both trials, measured water loss through the skin decreased more with krill oil.1 g: mean change −0.65 versus +0.13 g/m²/h; 2 g: −1.23 versus −0.24 | 1/4 Very lowStudies were small or had methodological shortcomings; missing data and selective reporting are possible. Results varied greatly or were heterogeneous. Different products, administration methods, participant groups or indirect measures were used. A confidence interval is provided, but the precision of the pooled estimate remains uncertain. The influence of publication bias could not be assessed. | 22 separate trialsKrill oil supplementation improves transepidermal water loss, hydration and elasticity of the skin in healthy adults: Results from two randomized, double-blind, placebo-controlled, dose-finding pilot studies. ↗ | Healthy adults in two separate small trials. | - Krill oil supplementation improves transepidermal water loss, hydration and elasticity of the skin in healthy adults: Results from two randomized, double-blind, placebo-controlled, dose-finding pilot studies. ↗
|
|---|
| Headache days in migraine | On average, headache occurred on 2.39 fewer days per month than in the control groups.Mean difference −2.39 days per month, 95% CI −3.78 to −1.00; very low certainty | 1/4 Very lowStudies were small or had methodological shortcomings; missing data and selective reporting are possible. Results varied greatly or were heterogeneous. Different products, administration methods, participant groups or indirect measures were used. A confidence interval is provided, but the precision of the pooled estimate remains uncertain. The influence of publication bias could not be assessed. | 11 systematic review; 7 trials for this outcomeDosing effects of omega-3 fatty acid interventions in adults with migraine: Systematic review and meta-analysis of randomized clinical trials ↗ | Adults with migraine: seven studies with 652 participants. | - Dosing effects of omega-3 fatty acid interventions in adults with migraine: Systematic review and meta-analysis of randomized clinical trials ↗
|
|---|
| Menstrual pain | In the review, menstrual pain decreased on average with the products studied.Standardised difference d −1.02, 95% CI −1.53 to −0.51; I² 89% | 1/4 Very lowStudies were small or had methodological shortcomings; missing data and selective reporting are possible. Results varied greatly or were heterogeneous. Different products, administration methods, participant groups or indirect measures were used. A confidence interval is provided, but the precision of the pooled estimate remains uncertain. The influence of publication bias could not be assessed. | 11 systematic review; 8 trials for this outcome (9 comparisons)Omega-3 long chain polyunsaturated fatty acids as a potential treatment for reducing dysmenorrhoea pain: Systematic literature review and meta-analysis. ↗ | Girls and women aged 13–33 with menstrual pain. | - Omega-3 long chain polyunsaturated fatty acids as a potential treatment for reducing dysmenorrhoea pain: Systematic literature review and meta-analysis. ↗
|
|---|
| Weight and body composition during calorie restriction | No convincing additional reduction in weight or fat mass or preservation of fat-free mass was found.Body weight: standardised mean difference −0.05 (−0.22 to 0.13); fat mass −0.01 (−0.25 to 0.24); fat-free mass +0.12 (−0.14 to 0.37) | 2/4 LowSome studies were small, with a risk of bias and incomplete reporting. Interventions and outcomes varied; study results could conflict. The assessment is limited to the stated group and measured outcome. The pooled result and confidence interval are provided. Publication bias cannot be ruled out. | 11 systematic review; 11 trials in the whole reviewEffects of Long-Chain n-3 Fatty Acids Supplementation During Caloric Restriction on Body Composition in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ↗ | Adults with overweight; the review included 11 studies with 637 participants. | - Effects of Long-Chain n-3 Fatty Acids Supplementation During Caloric Restriction on Body Composition in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ↗
|
|---|
| Thinking in older VITAL-Cog participants | No convincing improvement in the overall thinking test score was found.difference in annual change in the overall thinking score −0.01 standardised units, 95% CI −0.02 to +0.003 | 2/4 LowNot all participants completed repeat tests; missing data and selection of substudy participants may have affected the result. Cognitive results came from two substudies with different testing methods and follow-up durations. The assessment is limited to the stated group and measured outcome. A confidence interval is provided for the difference in annual change in the overall test score. Publication bias cannot be ruled out. | 11 randomised trialMarine n-3 fatty acids and cognitive change among older adults in the VITAL randomized trial. ↗ | Older VITAL-Cog substudy participants: 3424 in the telephone group and 794 in the in-person group. | - Marine n-3 fatty acids and cognitive change among older adults in the VITAL randomized trial. ↗
|
|---|
| Dry eye symptoms: DREAM trial | No convincing relief of symptoms compared with the control oil was found.Difference in change −1.9 points (95% CI −5.0…1.1). | 3/4 ModerateNo additional substantial reasons to doubt the reliability of the result were identified for this comparison. There are no grounds for a separate downgrade. The study tested the specific form, participant group and outcome stated. The interval still allows a small effect. There are no specific data for a separate downgrade. | 11 randomised trialn-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. ↗ | Adults aged 18 and over with moderate or severe dry eye disease for at least six months; concomitant care was allowed. | - n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. ↗
|
|---|
| Strength recovery after exercise | The EPA and DHA products studied may help restore strength after exercise that causes substantial muscle damage.Hedges g +0.45 (95% CI 0.07–0.83); the result does not concern long-term strength gains. | 1/4 Very lowSmall trials and different assessment methods. There are no grounds for a separate downgrade. Different products and protocols. The interval covers effects from small to noticeable. There are no specific data for a separate downgrade. | 11 systematic review; the set of placebo-controlled trials in the review is 9Effects of LC n-3 PUFA Supplementation on Muscle Pain, Function, and Damage Markers in Healthy Young to Middle-Aged Adults Following Acute or Chronic Exercise: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ↗ | Healthy young and middle-aged adults in placebo-controlled studies of exercise that lengthens the working muscle. | - Effects of LC n-3 PUFA Supplementation on Muscle Pain, Function, and Damage Markers in Healthy Young to Middle-Aged Adults Following Acute or Chronic Exercise: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ↗
|
|---|
| Pain in osteoarthritis | The omega-3 products studied may slightly reduce pain.Standardised mean difference −0.29 (95% CI −0.47…−0.11), I² 60% | 1/4 Very lowHeterogeneous methods across individual trials. Differences in results and protocols. Products and clinical situations vary. There are enough data for a limited conclusion. There are no specific data for a separate downgrade. | 11 systematic review; 9 trials in the whole reviewEffect of omega-3 polyunsaturated fatty acids supplementation for patients with osteoarthritis: a meta-analysis. ↗ | Adults with osteoarthritis in the relevant trials. | - Effect of omega-3 polyunsaturated fatty acids supplementation for patients with osteoarthritis: a meta-analysis. ↗
|
|---|
| Everyday physical function in osteoarthritis | The omega-3 products studied slightly improved the rating of everyday physical function.Standardised mean difference −0.21 (−0.34…−0.07) | 2/4 LowHeterogeneous methods across individual trials. There are no grounds for a separate downgrade. Products and clinical situations vary. There are enough data for a limited conclusion. There are no specific data for a separate downgrade. | 11 systematic review; 9 trials in the whole reviewEffect of omega-3 polyunsaturated fatty acids supplementation for patients with osteoarthritis: a meta-analysis. ↗ | Adults with osteoarthritis in the relevant trials. | - Effect of omega-3 polyunsaturated fatty acids supplementation for patients with osteoarthritis: a meta-analysis. ↗
|
|---|